Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
181-200 of 1,738 trials

Multiple Myeloma: HUVR-CARTemis-1 T-Cell Therapy

We are studying a new T-cell therapy for patients with multiple myeloma who have relapsed after an allogeneic transplant. The trial aims to evaluate the safety and effectiveness of this treatment over time.

Multiple Myeloma Progression>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Gastrointestinal Stromal Tumors: Imatinib and Atezolizumab Study

We are investigating whether combining imatinib with atezolizumab helps patients with advanced GIST who have not responded to other treatments. The study aims to assess survival rates and quality of life improvements.

Unresectable Gastrointestinal Stromal Tumor (GIST)Metastatic Gastrointestinal Stromal TumorLocally Advanced Gastrointestinal Stromal Tumor (GIST)>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Hodgkin Lymphoma: Tislelizumab Treatment Study

We are evaluating the safety and effectiveness of tislelizumab for patients with untreated Hodgkin lymphoma who cannot undergo standard chemotherapy. This study aims to see how well this treatment works and how it is tolerated.

Classical Hodgkin LymphomaEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Fabry Disease: PRX-102 for Children and Teens

We are studying the safety and effects of the drug PRX-102 in children and adolescents with Fabry disease. This research aims to understand how well it works and how it is processed in young patients.

Fabry's Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Recurrent Solid Tumors: IMA402 Treatment Study

We are testing a new treatment called IMA402 for patients with recurrent or hard-to-treat solid tumors. The study aims to evaluate its safety and how well it works, both alone and with another medication.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Alzheimer's Disease: PRI-002 Study

We are testing a new medication, PRI-002, for individuals with mild cognitive impairment or mild dementia due to Alzheimer's disease. The study aims to evaluate its safety and effectiveness in improving cognitive function.

Alzheimer's Disease1-2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Fremanezumab for Pain in Complex Regional Pain Syndrome

We are studying whether fremanezumab can reduce pain in patients with Complex Regional Pain Syndrome compared to a placebo. The trial also examines how this treatment affects disease symptoms and function.

Complex Regional Pain Syndrome≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementNeurology

Sotorasib for Advanced Lung Cancer with KRAS G12C Mutation

We are studying whether sotorasib can help reduce tumor size in patients with advanced lung cancer who have other health conditions. The trial also looks at quality of life and safety during treatment.

KRAS G12C-Mutated Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

PDA Treatment in Premature Infants: Acetaminophen and Ibuprofen Study

We are studying whether combining acetaminophen with ibuprofen helps extremely premature infants with a heart condition. The goal is to see if this combination reduces serious complications compared to ibuprofen alone.

Patent Ductus Arteriosus≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesCardiologyPediatrics

Systemic Sclerosis-Associated Lung Disease: Belimumab Study

We are testing whether belimumab can improve lung function and reduce skin thickening in adults with systemic sclerosis-related lung disease. This study compares its effects to a placebo alongside standard treatment.

Systemic Sclerosis Associated Interstitial Lung Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPulmonologyRheumatology

Advanced Non-Small Cell Lung Cancer: Cemiplimab and BNT116 Combination

We are studying how a new cancer vaccine combined with cemiplimab works for adults with advanced non-small cell lung cancer. This trial will help us understand its effectiveness and safety compared to cemiplimab alone.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Colorectal Cancer: Flu Vaccine and Pembrolizumab Study

We are exploring whether a flu vaccine combined with pembrolizumab can help shrink tumors in patients with early pMMR colorectal cancer. The study will also assess safety and immune responses.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Ureter Visualization: Nizaracianine Triflutate in Surgery

We are studying a new intravenous drug to help surgeons see the ureters more clearly during abdominopelvic surgeries. This may improve safety and reduce the need for invasive procedures.

Urinary Tract ImagingEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOtolaryngologyUrology

Mitapivat for Erythrocyte Membranopathies

We are studying the safety and effects of mitapivat in adults with erythrocyte membranopathies. This includes looking at hemoglobin levels and how it may help with symptoms.

Erythrocyte Membranopathies>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Bronchiectasis: Long-Term Study of BI 1291583

We are testing the long-term safety of BI 1291583 in people with bronchiectasis who have taken part in earlier studies. The study will also look at whether this treatment helps reduce lung flare-ups.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Biliary Tract Cancer: GAP Chemotherapy Study

We are studying whether a combination of chemotherapy before surgery helps patients with biliary tract cancers live longer and have better outcomes than those who undergo surgery right away.

Biliary Tract CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Delayed Gastric Emptying: Nicotine Patch Study

We are investigating whether a nicotine patch can help patients who have had pancreatoduodenectomy by reducing delayed gastric emptying. The study also looks at the safety and tolerability of this treatment compared to a placebo.

Pancreatoduodenectomy≤3 monthsEfficacy phase (II)Investigational MedicinesGastroenterologyInternal Medicine

Ovarian Cancer Diagnosis: IMPROCAS Study

We are exploring new blood test methods and imaging techniques to improve how ovarian cancer is diagnosed. This study aims to create a better model for identifying the disease and understanding its severity.

Ovarian CancerEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesGynecology and ObstetricsInternal MedicineOncology

E. coli Urinary Tract Infection: Pivmecillinam Treatment

We are studying whether an oral medication called pivmecillinam is as effective as standard treatments for E. coli urinary tract infections. This trial will also assess safety and other health effects.

Febrile Urinary Tract Infection>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesUrology

HER2-Positive Metastatic Cancer: Trastuzumab Emtansine Study

We are providing ongoing treatment with trastuzumab emtansine for patients who previously benefited from this therapy. The study aims to assess the safety of long-term use, either alone or with other cancer treatments.

Metastatic Breast CancerEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology